|drug2639||Prescription Opioid Management App Wiki||1.00|
|D053120||Respiratory Aspiration NIH||0.29|
|D012120||Respiration Disorders NIH||0.26|
|D012140||Respiratory Tract Diseases NIH||0.21|
There is one clinical trial.
The purpose of this open label, randomized, study is to obtain information on the safety and efficacy of 80 ppm Nitric Oxide given in addition to the standard of care of patients with COVID-19 caused by SARS-CoV-2.
Description: Time to deterioration measured by need for NIV, HFNC or intubationMeasure: Time to deterioration Time: 14 Days
Description: Time to non-invasive ventilationMeasure: Time to NIV Time: 14 Days
Description: Time to high flow nasal cannulaMeasure: Time to HFNC Time: 14 Days
Description: Time to intubationMeasure: Time to intubation Time: 14 days
Description: Time to patient having stable oxygen saturation (SpO2) of greater than or equal to 93%Measure: Time to patient having stable oxygen saturation (SpO2) of greater than or equal to 93% Time: 14 days
Description: Need for supplemental oxygenMeasure: Need for supplemental oxygen Time: 14 days
Description: Change in viral loadMeasure: Change in viral load Time: 30 days
Description: Duration of the Hospital Length of Stay (LOS)Measure: Duration of the Hospital Length of Stay (LOS) Time: 14 days
Description: Mortality rate at Day 30Measure: Mortality rate at Day 30 Time: 30 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports